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Abstract
Background: The lack of approved treatments for the majority of rare diseases is reflective of the unique
challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are
needed to render the development process more feasible and appropriate for these rare populations and thereby
expedite the approval of promising treatments to address patients’ high unmet medical need. Here, we describe
the development of an innovative master protocol and primary outcome assessment to investigate the modified
amino acid N-acetyl-L-leucine (Sponsor Code: IB1001) in three separate, multinational, phase II trials for three ultra-
rare, autosomal-recessive, neurodegenerative disorders: Niemann-Pick disease type C (NPC), GM2 gangliosidoses
(Tay-Sachs and Sandhoff disease; “GM2”), and ataxia telangiectasia (A-T).
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Methods/design: The innovative IB1001 master protocol and novel CI-CS primary endpoints were developed
through a close collaboration between the Industry Sponsor, Key Opinion Leaders, representatives of the Patient
Communities, and National Regulatory Authorities. As a result, the open-label, rater-blinded study design is
considerate of the practical limitations of recruitment and retention of subjects in these ultra-orphan populations.
The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the
heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the principal investigator appoints for each
patient a primary anchor test (either the 8-m walk test (8MWT) or 9-hole peg test of the dominant hand (9HPT-D))
based on his/her unique clinical symptoms. The anchor tests are videoed in a standardized manner at each visit to
capture all aspects related to the patient’s functional performance. The CI-CS assessment is ultimately performed by
independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end
of treatment, and the end of a post-treatment washout. Blinded to the time point of each video, the raters make
an objective comparison scored on a 7-point Likert scale of the change in the severity of the patient’s neurological
signs and symptoms from video A to video B. To investigate both the symptomatic and disease-modifying effects
of treatment, N-acetyl-L-leucine is assessed during two treatment sequences: a 6-week parent study and 1-year
extension phase.
Discussion: The novel CI-CS assessment, developed through a collaboration of all stakeholders, is advantageous in
that it better ensures the primary endpoint is functionally relevant for each patient, is able to capture small but
meaningful clinical changes critical to the patients’ quality of life (fine-motor skills; gait), and blinds the primary
outcome assessment. The results of these three trials will inform whether N-acetyl-L-leucine is an effective treatment
for NPC, GM2, and A-T and can also serve as a new therapeutic paradigm for the development of future treatments
for other orphan diseases.
Trial registration: The three trials (IB1001-201 for Niemann-Pick disease type C (NPC), IB1001-202 for GM2
gangliosidoses (Tay-Sachs and Sandhoff), IB1001-203 for ataxia telangiectasia (A-T)) have been registered at www.
clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678), www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71;
2018-004406-25; 2018-004407-39), and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539;
DRKS00020511).
Keywords: Niemann-Pick disease type C (NPC), GM2 gangliosidosis, Tay-Sachs disease (TSD), Sandhoff disease,
Ataxia telangiectasia, N-acetyl-L-leucine, Pharmaceutical intervention, Symptomatic treatment, Single-blinded trial,
Cerebellar ataxia, Lysosomal storage disease
Background
The Orphan Drug Act of 1983 [1] defines rare (“or-
phan”) diseases as those which affect 200,000 or fewer
individuals in the USA. Recently, advances in diagnostic
techniques, particularly next-generation sequencing of
DNA, have led to the rapid expansion in the number of
recognized “ultra-rare diseases,” proposed to describe
disorders with a prevalence of less than 1:100,000 indi-
viduals [2]. It is now estimated there are over 10,000 rare
and ultra-rare diseases which, although individually rare
in prevalence, are collectively estimated to affect some
30 million Americans [3]. For over 95% of these disor-
ders there are no US Food and Drug Administration
(FDA)-approved treatments [4].
The lack of approved orphan drugs reflects the unique
challenges of orphan drug development. The conven-
tional pathway to drug approval is often unsuitable for
rare diseases and raises hurdles that cannot be easily
overcome, if at all [5, 6]. Novel drug-development strat-
egies are needed to render the regulatory and develop-
ment processes more feasible and cost-effective and
more quickly address the extremely high unmet medical
need of orphan diseases [7].
One response to expedite the development of novel
treatments for rare diseases is to utilize a master proto-
col, where a single drug can be investigated for multiple
indications. These may take three forms:
(i) Umbrella trials, which study multiple targeted
therapies in a single disease;
(ii) Platform trials, in which multiple targeted therapies
are studied in a single disease on an ongoing basis.
Therapies are added or subtracted to the platform
on the basis of previously agreed algorithms, with
therapies allowed to enter or leave the platform on
the basis of a decision algorithm;
(iii)Basket studies, in which a single targeted therapy is
studied in multiple diseases, or disease subtypes [8].
Here, we describe the development of a master proto-
col comprising three separate basket studies to investi-
gate a novel agent, N-acetyl-L-leucine (Sponsor Code:
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IB1001), as a therapy for three different ultra-rare neuro-
degenerative diseases: Niemann-Pick disease type C
(NPC), GM2 gangliosidoses (Tay-Sachs and Sandhoff
diseases; “GM2”), and ataxia telangiectasia (A-T), which
share cerebellar ataxia as a common central
manifestation.
Protocol references
IB1001-201 investigates N-acetyl-L-leucine for the treat-
ment of Niemann-Pick disease type C (NPC). NPC is an
ultra-rare (1:120,000), prematurely fatal, autosomal reces-
sive, neurovisceral lysosomal storage disease that predom-
inantly affects children. However, adolescent and adult
onset cases are being increasingly recognized [9, 10].
Treatment of NPC is so far limited to reducing the rate of
disease progression with the substrate reduction therapy
drug miglustat (Zavesca™ [11]), approved in the European
Union and several other countries, but not in the USA.
IB1001-202 investigates N-acetyl-L-leucine for the
treatment of the GM2 gangliosidoses (Tay-Sachs and
Sandhoff diseases; “GM2”). GM2 is an ultra-rare (0.28:
100,000), prematurely fatal, autosomal recessive, neuro-
visceral lysosomal storage disorder that predominantly
and most severely affect pediatric patients [12]. There is
currently no approved treatment in any jurisdiction for
GM2.
IB1001-203 investigates N-acetyl-L-leucine for the
treatment of ataxia telangiectasia (A-T). A-T is an ultra-
rare (1:40,000–100,000), autosomal recessive, cerebellar
ataxia that predominantly affects pediatric patients [13].
There is currently no approved treatment in any juris-
diction for A-T.
Despite their different etiologies, NPC, GM2, and A-T
are all characterized by progressive neurodegeneration
of the cerebellum and cerebrum, resulting in physical
and cognitive decline, and premature death. Each dis-
order manifests systemic, neurological, and neuro-
psychological findings. The three disorders share a
number of hallmark symptoms, in particular, cerebellar
ataxia, dysarthria, and dysphagia. Owing to their com-
mon neurological manifestations, and the mechanism of
action of the investigational product N-acetyl-L-leucine,
a single master protocol has been developed for the
three disorders.
N-acetyl-L-leucine
N-acetyl-L-leucine is the L-enantiomer of N-acetyl-
leucine, a modified amino acid that has been available in
France since 1957 as a racemate (equal amounts of both
D- and L-enantiomers) under the trade name Tanganil®
(Pierre Fabre Laboratories) as a treatment for acute ver-
tigo. N-acetyl-L-leucine is not approved for any indica-
tion in any jurisdiction.
The mechanisms of action of N-acetyl-DL-leucine for
vertigo are not fully understood. It may act directly on
neurons; in the vestibular nuclei, N-acetyl-DL-leucine has
been shown to restore membrane potential in hyperpo-
larized/depolarized vestibular neurons following unilat-
eral labyrinthectomy in guinea pigs [14]. This effect may
be mediated by N-acetyl-DL-leucine’s direct interactions
with membrane phospholipids such as phos-
phatidylinositol 4,5-bisphosphate, which influence ion
channel activity [15]. Thus, N- acetyl-DL-leucine can
normalize neuronal function. In patients with a unilat-
eral neurotomy and labyrinthectomy, the agent was de-
scribed to normalize the vestibular asymmetry, showing
an effect only in the subgroup of individuals with re-
sidual vestibular function [16].
Subsequent studies in models of vertigo on the indi-
vidual enantiomers have revealed that the therapeutic ef-
fects of N-acetyl-DL-leucine are due to the L-enantiomer.
Studies of a rat model of unilateral labyrinthectomy re-
vealed that N-acetyl-L-leucine, but not N-acetyl-D-leu-
cine, is the pharmacologically active substance that
improves central vestibular compensation [17]. Further-
more, a study in a unilateral vestibular neurectomy cat
model suggested that N-acetyl-L-leucine is the enantio-
mer that leads to a significant acceleration of the ves-
tibular compensation process, most likely acting on
vestibular nuclei neurons [18].
Given the phylogenetic and electrophysiological simi-
larities and close interactions between vestibular and
deep cerebellar neurons, it was hypothesized both N-
acetyl-DL-leucine and therefore also N-acetyl-L-leucine
may have clinical utility in the treatment of cerebellar
symptoms that occur in diseases such as NPC through a
similar mechanism as that observed in models of vertigo,
acting on neurons. However, in vitro experiments using
non-neuronal, Npc1-deficient Chinese hamster ovary
cells or fibroblasts derived from patients with NPC dem-
onstrated N-acetyl-L-leucine and N-acetyl-DL-leucine
also reverse disease-related cellular phenotypes in non-
neuronal cells, including expanded lysosomal volume,
with superior efficacy resulting from the L-enantiomer
[19]. The mechanisms leading to effects on lysosomal
storage in non-neuronal cells are currently under
investigation.
N-acetyl-L-leucine has also been demonstrated to re-
duce neuroinflammation in the cerebellum. Activated
microglia are associated with the neurodegenerative and
neuroinflammatory components of cerebellar disorders,
as engulfment of neuronal processes by microglia pre-
cede Purkinje cell death (an important type of nerve cell
involved in movement control). In vivo studies in a
mouse model for traumatic brain injury demonstrate
treatment with N-acetyl-L-leucine improves lysosome-
related autophagy flux and thereby restores its
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neuroprotective function in the cortices after traumatic
brain injury [20]. This is expected to lead to the attenu-
ation and restrict neuronal cell death, hence improving
neurological function [20]. As acute and prolonged neu-
roinflammation contribute to neuronal death, these re-
sults suggest that N-acetyl-L-leucine may protect cells
from neurodegeneration arising from genetic or acquired
neurological disorders.
Trial rationale
The development of N-acetyl-leucine for NPC, GM2,
and A-T began with the investigation of the commer-
cially available racemic mixture, N-acetyl-DL-leucine
(Tanganil®). In a case series of 12 patients with NPC, it
was shown that N-acetyl-DL-leucine (3 g/day for 1 week
followed by 5 g/day for 3 weeks) significantly improved
the symptoms of NPC after 4 weeks of treatment, mea-
sured by the Scale for the Assessment and Rating of
Ataxia (SARA), the Spinocerebellar Ataxia Functional
Index (SCAFI), and EuroQol-5D-5L. N-acetyl-DL-leucine
was well tolerated, and no side effects except for inter-
mittent dizziness were reported [21]. An additional case
series describes the disease-modifying effect of long-
term treatment with N-acetyl-DL-leucine in 10 patients
with NPC treated for a median length of 7.7 months
(maximum 21.2, minimum 2.7 months) [22].
The clinical utility of N-acetyl-DL-leucine for the treat-
ment of Tay-Sachs, Sandhoff, and A-T has also been in-
vestigated in a compassionate-use case-series, as well as
a variety of inherited cerebellar ataxias [23–25]. In all
studies, the compound was well-tolerated with no dis-
cernible serious side effects.
These preliminary clinical findings have been sup-
ported by in vitro studies in NPC and GM2 gangliosi-
doses patient cell lines, and in vivo studies in the NPC
(Npc1−/−) and Sandhoff (Hexb−/−) mouse models, which
corroborate the pharmacological properties of N-acetyl-
L-leucine and N-acetyl-DL-leucine in relation to the ob-
served therapeutic effects (Ecem Kaya and Frances Platt,
personal communication) [19]. These non-clinical stud-
ies have demonstrated the L-enantiomer, i.e., acetyl-L-
Leucine, is believed to have potential clinical benefits
compared to the racemic mixture [14–16]. Further,
pharmacokinetic studies suggest that the D-enantiomer
could accumulate relative to the L-enantiomer during
chronic administration of the racemate, which has the
potential for long term negative effects [26].
The development of N-acetyl-L-leucine has therefore
been initially prioritized for the treatment of NPC, GM2,
and A-T based on the existing pre-clinical and clinical
data in these three disorders demonstrating safety and
significant efficacy and the high unmet medical need of
each indication. Following the IB1001 clinical trials, it is
planned to investigate N-acetyl-L-leucine for the
treatment of additional rare disorders, including com-
mon ataxias, as well as rare and common neurological
disorders.
Rare disease trial design
NPC, GM2, and A-T are progressive, life-threatening
conditions with limited or no approved drugs, mandat-
ing greater urgency for trials to be conducted as effi-
ciently as possible to maximize the chance they can be
made available before the window of therapeutic oppor-
tunity is lost. However, like many clinical trials for rare
and ultra-rare diseases, there are a number of critical
protocol considerations which must be considered to do
so:
1. For each disorder, the potential pool of participants
is small, and within that circumscribed group, not
all individuals are willing to participate or suitable
candidates for clinical trials.
2. Parents and caregivers in these communities have
legitimate ethical concerns about placebo-
controlled trials. This may complicate and delays
the recruitment and completion of studies and, sub-
sequently, approval and availability of the treatment
for patients. The risk is even greater for trials like
IB1001 which involves a modified version of a com-
pound (Tanganil®) that is approved in France (as
well as Lebanon, Vietnam, and Tunisia) for use in
another clinical setting (acute vertigo) and which is
known to be widely used in an unlicensed setting
within these patient communities.
3. Each of these indications is characterized by broad
variability in the symptoms and signs of rare
diseases they exhibit, in the age at which they first
present, and the rate at which they progress. The
high inter-individual variability in the clinical course
of the disease renders an assembly of well-matched
cohorts of patients for controlled trials impossible.
4. Given the heterogeneity of the diseases, there are
significant limitations in selecting and prioritizing a
single outcome measure that can be considered
clinically meaningful for the entire patient
population.
Together, these factors significantly diminish a study’s
ability to detect a therapeutic effect. Thus, detecting a
statistically significant difference between intervention
and control groups is hard to achieve.
Collaboration
As a consequence of these challenges, many promising
treatments for orphan diseases will never surpass the de-
velopment hurdles and become approved for patients. In
too many instances, when a rare disease trial fails, it is
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not clear if this is a consequence of the compound’s lack
of a biological effect or an inadequate study design that
was not compatible with what can be reasonably
achieved within the rare disease patient population. To
avoid this pitfall in the IB1001 studies, an innovative
master protocol and novel primary outcome measure
were developed through a close collaboration between
Regulatory Agencies, Key Opinion Leaders—including
clinicians and patient communities—and the industry
sponsors. Such cooperation was essential to create a trial
design founded on a strong scientific rationale, but also
taking into account the demographics of these
heterogenous, rare populations. It is our hope that the
collaboration between these stakeholders and resulting
development program for IB1001 represent a model to




The IB1001-201 (NPC), IB1001-202 (GM2), and IB1001-
203 (A-T) clinical trials are separate multinational, mul-
ticenter, open-label, rater-blinded phase II studies. Each
trial will enroll approximately 30 patients. Subjects are
currently screened at 13 centers across Germany, Spain,
Slovakia, the UK, and the USA, including Ludwig Maxi-
milians University, Munich (201, 202, 203); University of
Giessen (201, 202, 203); Bellvitge University Hospital
(201, 202); Hospital University La Paz (203); Comenius
University in Bratislava (201); Great Ormond Street
Hospital (201); Royal Free Hospital (201); Royal Man-
chester Children’s Hospital (201, 202); Salford Royal
NHS Foundation Trust (201, 202); Royal Papworth Hos-
pital (203); The Mayo Clinic, Rochester MN (201, 202);
New York University Langone (202), and University of
California Los Angeles (202, 203).
Study oversight
The IB1001 trials are conducted in accordance with the
International Conference for Harmonisation (of Tech-
nical Requirements for Pharmaceuticals for Human Use)
- Good Clinical Practice Guideline, the General Data
Protection Regulator, and the Declaration of Helsinki.
The studies have been approved by the ethics commit-
tees of each participating center and the regulatory au-
thorities in each respective country. The safety, integrity,
and feasibility of the trial is monitored by an independ-
ent data safety monitoring board (DSMB) consisting of
three independent, non-participating members (includ-
ing two clinicians and a statistician). The function of the
DSMB is to monitor the course of the studies and, as ap-
plicable, give a recommendation to the Sponsor of the
trial for discontinuation, modification or continuation of
the study.
Patient population and eligibility criteria
Patients are screened for eligibility according to the in-
clusion and exclusion criteria. To be eligible for the re-
spective study, patients with a confirmed diagnosis of
NPC, GM2, or A-T (aged ≥ 6 years in Europe and ≥ 18
years in the USA) must present with clinical symptoms,
provide appropriate informed consent, and undertake a
washout of any prohibited medications (if applicable).
These include any variant of N-acetyl-DL-leucine (e.g.,
Tanganil®). For a detailed description of the inclusion
and exclusion criteria, see Table 1.
Recruitment and patient involvement
Patients are recruited via personal correspondence, rou-
tine care appointments, and referrals. In addition, there
is tremendous collaboration and support from multi-
national patient organizations representing these rare
disease communities.
The principal investigator at each trial site is respon-
sible for obtaining informed consent for each patient.
All eligible patients who agree to participate in the study
are provided with a full verbal explanation of the trial
and the patient information sheet. This includes detailed
information about the rationale, design, and personal
implications of the study.
Study design and procedures
The IB1001 clinical trials are open-label, rater-blinded
studies. During the development of the IB1001 master
protocol, the appropriateness of initiating a randomized,
double-blind, controlled studies for these ultra-orphans
was strongly questioned by clinical experts and represen-
tatives of the patient communities, given the diseases’ re-
lentless and often rapid progression, prematurely fatal
outcome, and lack of alternative treatment options. A
formal feasibility study was initiated by the Sponsor that
demonstrated that a long-term, randomized, double-
blind, placebo-controlled, crossover study would be diffi-
cult to recruit and carry out without changes to the
study design. This was largely attributed to the known,
widespread, off-label/unlicensed use of N-acetyl-DL-leu-
cine (Tanganil®). Patients and families expressed reluc-
tance to participate in a placebo-controlled study where
they would be required to washout from this off-label/
unlicensed medication and receive an inactive treatment
for even 50% of the time.
In order to assure the feasibility of recruitment, an
open-label study schema is used. Based on observational
and pre-clinical studies that demonstrate the potential of
symptomatic benefit of treatment in as little as 4 weeks
[21, 23], in the first treatment sequence (“parent study”),
patients are assessed during three study phases: a base-
line period (with or without a study run-in), a treatment
period of 6 weeks (42–49 days), and a washout period of
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6 weeks (42–49 days). Patients will be assessed twice
during each period to allow an assessment of intra-
patient variability.
At the initial screening visit, patients will be classified
as either “naïve” or “non-naïve” depending on their use
of prohibited medications within the past 6 weeks (42
days). The schedule of events during the initial screening
visit and throughout the baseline period (through visit 1)
will vary depending on the patient’s classification as ei-
ther “naïve” or “non-naïve.”
Given the known unlicensed use of the racemate (Tan-
ganil®), for all patients, a urine sample will be taken at visit
1 to detect N-acetyl-D-leucine using a validated liquid
chromatography mass spectrometry/mass spectrometry
method. Provided the level of N-acetyl-D-leucine tests
below the permitted threshold, the initial screening visit
will be confirmed as visit 1 (baseline 1). If a patient classi-
fied as “Naïve” unexpectedly tests positive for levels of N-
acetyl-D-leucine above the permitted threshold, at the dir-
ection of their principal investigator, a run-in wash-out
period of 6 weeks (42 days) is requested before they are
eligible to return for a repeat visit 1. Patients who fail two
urine N-acetyl-D-leucine tests (e.g., visit 1 and repeat visit
1) are ineligible for the study.
Figure 1 displays the naïve and non-naïve study
schemes for the parent study. Suppl. Table 1 lists the
schedule of enrolment and assessments together with
pre-planned time points for clinic visits during.
Patients who have completed visit 6 of the parent
study have the opportunity to continue treatment with
N-acetyl-L-leucine (IB1001) in an extension phase if the
principal investigator determines it is in their best inter-
est. The extension phase consists of a 1-year (351–379
days) treatment period followed by a 6 weeks (42–56
days) washout period. Table 2 lists the inclusion criteria
for the extension phase. Figure 2 displays the extension
phase study schema. Suppl. Table 2 lists the schedule of
enrolment and assessments together with pre-planned
time points for clinic visits in the extension phase.
Study drug
In the parent study, the dosage formulation of N-acetyl-
L-leucine is 1000 mg powder for oral suspension (manu-
facture: Patheon UK Limited, Oxfordshire, UK) which is
suspended in 40 mL Ora-Blend®.
In the extension phase, the dosage form of N-acetyl-L-
leucine is 1000 mg granules for oral suspension in a sa-
chet (manufacture: Patheon UK Limited, Oxfordshire,
UK, and Patheon France S.A.S., Bourgoin, France) which
is suspended in 40mL water.
Administration and study drug dosage
During the treatment periods for both treatment se-
quences, the dosing of the study drug is as follows:
Patients aged ≥ 13 years or aged 6–12 years weighing ≥
35 kg will take 4 g/day (2 g in the morning, 1 g in the
afternoon, and 1 g in the evening). Patients aged 6–12
years weighing 25 to < 35 kg will take 3 g/day (1 g in the
morning, 1 g in the afternoon, and 1 g in the evening).
Patients aged 6–12 years weighing 15 to < 25 kg will take
2 g/day (1 g in the morning and 1 g in the evening).
Medication should be taken at least 30 min before or at
least 2 h after a meal.
If adverse events are noted, patients are permitted to
down-titrate to one-half their daily dose, at the direction
of the investigator. Compliance will be assessed upon a
review of the inventory of IB1001 bottles/sachets
returned by patients.
Study objectives
The two treatment sequences in the parent study and
extension phase enable the investigation of both the
symptomatic (6 week) and long-term (1 year) safety and
efficacy of treatment with N-acetyl-L-leucine.
The primary objective of both treatment sequences is
to evaluate the efficacy of N-acetyl-L-leucine based on
blinded raters’ Clinical Impression of Change in Sever-
ity© (CI-CS) in the treatment of NPC, GM2, or A-T.
The secondary objectives are:
 To assess the clinical efficacy (symptomatic and
long-term) of N-acetyl-L-Leucine on symptoms of
ataxia, functioning, and quality of life for patients
with NPC, GM2, or A-T;
 To evaluate the safety and tolerability of N-acetyl-
L-leucine at 4 g/day in patients with NPC, GM2,
or A-T, including patients aged ≥ 18 years in the
USA and patients aged ≥ 13 years in Europe, and
weight-tiered doses in patients 6 to 12 years of
age in Europe.
In the extension phase, an additional secondary object-
ive is to characterize the pharmacokinetics of N-acetyl-
L-leucine in patients with NPC, GM2, or A-T.
Safety and efficacy parameters
Primary efficacy endpoint
In light of the defined challenges to conducting an open-
label clinical trial in these ultra-orphan diseases, a novel
primary endpoint, the Clinical Impression of Change in
Severity© (CI-CS) was developed.
The administration and assessment of the CI-CS in-
volves three tasks. Table 3 provides an overview of each
task, the responsible party and the time point at which it
is performed.
(1) Determine CI-CS primary anchor test (8MWT or
9HPT-D)
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Table 1 Inclusion and exclusion criteria for patient selection in the Parent Study
Inclusion Criteria Exclusion Criteria
Individuals who meet all of the following criteria are eligible to
participate in the study:
1. Written informed consent signed by the patient and/or their legal
representative/ parent/ impartial witness
2. IB1001-201 (NPC) EU: Male or female aged ≥6 years in Europe OR
≥18 years in the United States with a confirmed diagnosis of NPC at the
time of signing informed consent. Confirmed diagnosis includes
[Patterson et al, 2017]:
a) Clinical features and positive biomarker screen and/or filipin test
without genetic tests results (has not been performed)
b) Clinical features and positive genetic test
c) Clinical features and positive biomarker screen and/or filipin test but
only one NPC mutation identified on genetic test
d) Clinical features with positive biomarker screen and/or filipin test
and positive genetic test
IB1001-201 (NPC) US: Male or female aged ≥6 years in Europe OR ≥18
years in the United States with a confirmed diagnosis of NPC at the time
of signing informed consent. Patients must have clinical features of NPC
and a positive genetic test for mutations in both copies of NPC1 or in
both copies of NPC2.
IB1001-202 (GM2): Male or female aged ≥6 years in Europe OR ≥18
years in the United States with a confirmed diagnosis of GM2
Gangliosidosis at the time of signing informed consent. Confirmed
diagnosis, i.e., clinical features and positive genetic test GM2-
gangliosidosis caused by β-hexosaminidase deficiency resulting from
mutations in the HEXA or HEXB genes
IB1001-203 (A-T): Male or female aged ≥6 years in Europe OR ≥18 years
in the United States with a confirmed genetic diagnosis of A-T at the
time of signing informed consent.
3. Females of childbearing potential, defined as a premenopausal female
capable of becoming pregnant, will be included if they are either sexually
inactive (sexually abstinenta for 14 days prior to the first dose and
confirm to continue through 28 days after the last dose) or using one of
the following highly effective contraceptives (i.e. results in <1% failure
rate when used consistently and correctly) 14 days prior to the first dose
continuing through 28 days after the last dose:
a) intrauterine device (IUD);
b) surgical sterilization of the partner (vasectomy for 6 months
minimum);
c) combined (estrogen or progestogen containing) hormonal
contraception associated with the inhibition of ovulation (either oral,
intravaginal, or transdermal);
d) progestogen only hormonal contraception associated with the
inhibition of ovulation (either oral, injectable, or implantable);
e) intrauterine hormone releasing system (IUS);
f) bilateral tubal occlusion.
4. Females of non-childbearing potential must have undergone one of
the following sterilization procedures at least 6 months prior to the first
dose:
a) hysteroscopic sterilization;
b) bilateral tubal ligation or bilateral salpingectomy;
c) hysterectomy;
d) bilateral oophorectomy;
OR be postmenopausal with amenorrhea for at least 1 year prior to the
first dose and follicle stimulating hormone (FSH) serum levels consistent
with postmenopausal status. FSH analysis for postmenopausal women
will be done at screening. FSH levels should be in the postmenopausal
range as determined by the central laboratory.
5. Non-vasectomized male patient agrees to use a condom with
spermicide or abstain from sexual intercourse during the study until 90
days beyond the last dose of study medication and the female partner
agrees to comply with inclusion criteria 3 or 4. For a vasectomized male
who has had his vasectomy 6 months or more prior to study start, it is
required that they use a condom during sexual intercourse. A male who
has been vasectomized less than 6 months prior to study start must
follow the same restrictions as a non-vasectomized male.
6. If male, patient agrees not to donate sperm from the first dose until 90
days after their last dose.
Individuals who meet any of the following criteria are not eligible to
participate in the study:
1. Asymptomatic patients
2. Patient has clinical features of NPC and a positive biomarker screen
and/or filipin test, but a completely negative result on a previous genetic
test for NPC
3. Patients who have any of the following:
a) Chronic diarrhea;
b) Unexplained visual loss;
c) Malignancies;
d) Insulin-dependent diabetes mellitus.
e) Known history of hypersensitivity to the Acetyl-Leucine (DL-, L-, D-)
or derivatives.
f) History of known hypersensitivity to excipients of Ora-Blend® (namely
sucrose, sorbitol, cellulose, carboxymethylcellulose, xanthan gum,
carrageenan, dimethicone, methylparaben, and potassium sorbate).
4. Simultaneous participation in another clinical study or participation in
any clinical study involving administration of an investigational medicinal
product (IMP; ‘study drug’) within 6 weeks prior to Visit 1.
5. Patients with a physical or psychiatric condition which, at the
investigator’s discretion, may put the patient at risk, may confound the
study results, or may interfere with the patient’s participation in the
clinical study.
6. Known clinically-significant (at the discretion of the investigator)
laboratories in hematology, coagulation, clinical chemistry, or urinalysis,
including, but not limited to:
a. IB1001-201/ IB1001-202: Aspartate aminotransferase (AST) or
alanine aminotransferase (ALT) >5x upper limit of normal (ULN);IB1001-
203: Aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) >3x upper limit of normal (ULN);
b. Total bilirubin >1.5x ULN, unless Gilbert’s syndrome is present in
which case total bilirubin >2x ULN.
7. Known or persistent use, misuse, or dependency of medication, drugs,
or alcohol.
8. Current or planned pregnancy or women who are breastfeeding.
9. Patients with severe vision or hearing impairment (that is not corrected
by glasses or hearing aids) that, at the investigator’s discretion, interferes
with their ability to perform study assessments.
10. Patients who have been diagnosed with arthritis or other
musculoskeletal disorders affecting joints, muscles, ligaments, and/or
nerves that by themselves affects patient’s mobility and, at the
investigator’s discretion, interferes with their ability to perform study
assessments.
11. Patients unwilling and/or not able to undergo a 42-day washout
period from any of the following prohibited medication prior to Visit 1
(Baseline 1) and remain without prohibited medication through Visit 6.
a) Aminopyridines (including sustained-release form);
b) N-Acetyl-DL-Leucine (e.g. Tanganil®) ;
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Table 1 Inclusion and exclusion criteria for patient selection in the Parent Study (Continued)
Inclusion Criteria Exclusion Criteria
7. Patients must fall within:
a) A SARA score of 5 ≤ X ≤ 33 points (out of 40)
AND
b) Either:
i. Within the 2-7 range (0-8 range) of the Gait subtest of the SARA
scale
OR
ii. Be able to perform the 9-Hole Peg Test with Dominant Hand
(9HPT-D) (SCAFI subtest) in 20 ≤ X ≤150 seconds.
8. Weight ≥15 kg at screening.
9. Patients are willing to disclose their existing medications/therapies for
(the symptoms) of NPC, including those on the prohibited medication
list. Non-prohibited medications/therapies (e.g. miglustat, concomitant
speech therapy, and physiotherapy) are permitted provided:
a) The Investigator does not believe the medication/therapy will
interfere with the study protocol/results
b) Patients have been on a stable dose/duration and type of therapy
for at least 42 days before Visit 1 (Baseline 1)
c) Patients are willing to maintain a stable dose/do not change their
therapy throughout the duration of the study.
10. An understanding of the implications of study participation, provided
in the written patient information and informed consent by patients or
their legal representative/parent, and demonstrates a willingness to
comply with instructions and attend required study visits (for children
this criterion will also be assessed in parents or appointed guardians).
aSexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated
with the study treatments. In this trial abstinence is only acceptable if in line with the patient’s preferred and usual lifestyle
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhoea method
(LAM) are not acceptable methods of contraception. As well, female condom and male condom should not be used together
a)
b)
Fig. 1 Parent study schema. During the treatment period, all patients will receive N-acetyl-L-leucine for 42 days (+ 7 days). Visit 3 (treatment 1) will
occur at day 28 (+ 7 days) of the treatment period and visit 4 (treatment 2) will occur after the full 42 days (+ 7 days) of treatment. A 42-day (+ 7
days) washout period will be performed following treatment with N-acetyl-L-leucine. Visit 5 (washout 1) will occur on day 28 (+ 7 days) of the
washout period and visit 6 (washout 2) will occur after the full 42 days (+ 7 days) of washout. a Naïve patients screening pathway: patients who
have not used any prohibited medications within 42 days of screening are “naïve.” Their initial screening visit is treated as visit 1 (baseline 1). b
Non-naïve patient screening pathway: patients who have used or are unable to confirm or deny if they have used any prohibited medication
within the past 42 days are “non-naïve.” Patient will be given the opportunity to undergo a minimum of 42 days washout before returning for a
repeat visit 1 (baseline 1)
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Given the heterogeneity of symptoms, the appoint-
ment of a single symptom scale, such as either the 8-m
walk test (8MWT) or the 9-hole peg test of the domin-
ant hand (9HPT-D), as the primary outcome measure is
not appropriate for patient populations. To better ensure
the primary outcome measure is clinically meaningful
for each individual patient, at visit 1, the principal inves-
tigator selects either the 8MWT or 9HPT-D to be the
patient’s “primary anchor test.” The selection is guided
by pre-defined criteria based on patient’s performance
on ataxia rating scales (Spinocerebellar Ataxia Func-
tional Index (SCAFI) and Scale for the Assessment and
Rating of Ataxia (SARA)), as well as interactions with
the patient, their family, and/or caregivers. A cognitive
assessment is also performed at visit 1 according to the
standard procedures of the clinical site to select an an-
choring functional test which is appropriate for each pa-
tient from both a cognitive and a motor perspective. The
primary anchor test remains fixed for each patient for
the duration of the study.
(2) Video recordings: primary and non-primary anchor
tests
At each study visit (except visit 0), the 8MWT and
9HPT-D are videoed in a standardized manner by quali-
fied members of the study team. Video consultation has
been validated in other diseases and can minimize
variability in the data [27–29]. Out of necessity, the trials
are conducted at multiple study sites in different geo-
graphical locations, with inherent potential for consider-
able inter-rater variability in assessment scores [27].
Video recordings allow for centralized review and re-
peated viewing without the necessity for repetition and
patient fatigue [30].
Each clinical site must qualify two videographers be-
fore any patients are screened. All patient videos should
be performed by the same videographer, in the same en-
vironment, to ensure consistency and reduce the poten-
tial for variability. Videos will be collected by the clinical
sites and submitted to Medpace Core Laboratories via
the web based ClinTrak Imaging Windows Client Appli-
cation for collection, quality control, central review, and
storage. A more detailed description on the acquisition,
submission, and video review process is provided in
Suppl. Material I.
(3) CI-CS assessment of primary anchor test
The primary CI-CS assessment is performed by two,
independent raters based on the videos of each patient’s
primary anchor test acquired throughout the respective
treatment sequence (visits 1–6; visits 7–10). Prior to
their review of patient videos, the raters are trained on
existing videos to ensure standardization of the
assessments.
Table 2 Inclusion criteria for patient participation in the Extension Study
Inclusion Criteria
1. Completed Visit 6 of the IB1001-201 / IB1001-202 / IB1001-203 Parent Study
2. The Principal Investigator determines further treatment with IB1001 to be in patient’s best interest
3. Written informed consent signed by the patient and/or their legal representative/parent/ impartial witness for participation in the Extension Phase
4. Patients are willing to continue to remain without the following prohibited medication from Visit 6 throughout the duration the Extension Phase:
a) Aminopyridines (including sustained-release form);
b) N-Acetyl-DL-Leucine (e.g. Tanganil®);







Fig. 2 Extension phase schema. Patients will be assessed approximately 4 times over a 64-week period: at the start of the extension phase, after
6 months of treatment, 1 year of treatment, and after a 42-day (+ 14 day) post-extension-phase treatment washout
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Raters are asked to assess three video pairs:
 Pair A: (i) Baseline and (ii) end of treatment
 Pair B: (ii) End of treatment and (iii) end of washout
 Pair C: (iii) End of washout and (i) baseline
Pairs A, B, and C are reviewed by the raters in ran-
dom order. The internal pairing of videos (i) baseline,
(ii) end of treatment, and (iii) end of washout will
also be arranged randomly. The raters will be blinded
in this way to reduce detection and performance
biases.
For each pair, raters are asked to assess: “Compared to
the first video, how has the severity of the patient’s per-
formance on the 8MWT or 9HPT-D changed (improved
or worsened) as observed in the second video?” The CI-
CS assessment is based on a 7-point Likert scale ranging
from + 3 (significantly improved) to − 3 (significantly
worse). If there is a difference of one (1) point in the
two primary blinded raters’ CI-CS scores for a specific
video pairing, the two scores will be averaged. If there is
a difference greater than one (1) point between the two
primary blinded reviewers’ CI-CS scores for a specific
video pairing, an adjudication rating will be triggered. In
such cases, a third blinded rater will review the scores
given from each of the two primary independent raters
and determine which score is more accurate, that of
rater A or rater B (adjudication by consensus). The adju-
dicator’s decision will provide the final score for that
video assessment.
Primary endpoint definition
The primary endpoint is defined as:
Assessment A: the CI-CS comparing videos of the pa-
tient’s performance on the pre-defined anchor test at (i)
the end of treatment versus (ii) baseline; minus
Assessment B: the CI-CS comparing videos of the pa-
tient’s performance on the pre-defined anchor test at (i)
the end of washout versus (ii) end of treatment.
The CI-CS achieves the following: first, detection and
performance bias for the primary endpoint is reduced by
the blinded, independent review. Second, each patient’s
washout period (assessment B) serves as a control arm
to their treatment period (assessment A). Third, videos
increase reliability and minimize the burden on patients.
Finally, the CI-CS is a platform to capture and assess
small but clinically meaningful changes in patient’s per-
formance, which relate to their level of functioning and
quality of life, but which cannot be obtained from the
quantitative timed 8MWT or 9HPT-D assessments. This
is critical: although functioning typically improves with
symptom reduction, these concepts are not always con-
cordant [31]. For example, a change in gait velocity does
not necessarily account for the way gait patterns deviate
from normal (i.e., balance, variability, asymmetry,
rhythm, posture, or, notably, the ability to walk unaided
[23, 30]) and, therefore, a meaningful improvement in
ambulation. Similarly, a faster 9HPT score does not ne-
cessarily capture a change in fine-motor skills, grip, or
tremor wherein individuals may perform the test more
carefully or precisely which results, paradoxically, in an
increase in 9HPT time. Therefore, the CI-CS is a metric
of clinical importance that cannot be obtained from
traditional assessment measures.
In the extension phase, the primary endpoint is de-
fined as success on the Clinical Impression of Change in
Severity© (CI-CS) comparing videos of the primary an-
chor test at (i) the end of the extension phase treatment
with N-acetyl-L-leucine (visit 9) versus (ii) the extension
phase baseline (visit 7). Clinical benefit is defined as a
CI-CS value of 0 (no change) or better (≥ 1, at least some
improvement).
Secondary efficacy endpoints to supplement the analysis of
the primary endpoint
Supportive secondary endpoints will be evaluated that
directly supplement the analysis of the primary endpoint,
including the independent raters’ Clinical Impression of
Severity (CI-S). The raters will be given videos of the pa-
tient’s performance on the primary and non-primary an-
chor test acquired at each visit of the respective
treatment sequence (visits 1 to 6; visits 7 to 10). This will
enable the evaluation of both of the possible anchor tests
and assess the appropriateness of the chosen primary an-
chor test with regard to its ability to function as a clinic-
ally meaningful outcome measure for the patient. Again,
videos will be presented to the raters in a randomized,
blinded manner.
For each video, the raters are asked to assess: “Consid-
ering your total clinical experience with this particular
Table 3 Components of the Clinical Impression of Change in Severity© (CI-CS) Assessment
TASK TIMEPOINT RESPONSIBLE PERSON(S)
Determine CI-CS Primary Anchor Test (8MWT or
9HPT-D)
Visit 1 Principal Investigator
Anchor Tests Video Recordings Visit 2, 3, 4, 5, 6, 7, 8, 9, 10, Early Termination (as
applicable)
Qualified Video-Recorder (Study Team
Member)
CI-S & CI-CS Assessment Anchor Tests Following Last Visit (Parent Study: Visit 6; Extension
Phase: Visit 10)
Blinded Independent Raters
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population, how ill is the patient at this time?” The CI-S
is rated on a 7-point Likert scale ranging from + 3 (nor-
mal, not at all ill) to − 3 (among the most extremely ill
patients). For the CI-S, if there is any difference in the
two blinded reviewers’ scores, the two scores will be
averaged.
Secondary endpoints
Additional secondary endpoints will measure other
symptoms and evaluate quality of life. Descriptive statis-
tics will be provided for these measures at each visit and,
also, changes from [parent study/extension phase] base-
line (visit 2/visit 7) to the end of treatment with N-
acetyl-L-leucine (visit 4/visit 9), as well as end of treat-
ment with N-acetyl-L-leucine (visit 4/visit 9) to the end
of the post-treatment washout (visit 6/visit 10) for the
following measures:
 Spinocerebellar Ataxia Functional Index (SCAFI)
[32].
 Scale for Assessment and Rating of Ataxia (SARA)
score [32, 33].
 Quality of Life EQ-5D-5L for patients aged ≥ 18;
EQ-5D-Y for patients aged < 18 years [34].
 Modified Disability Rating Scale (mDRS) (201 and
202 study only) [35, 36].
 Clinical Global Impression Scales [37]:
 Investigator, caregiver, and patient (if able)
clinical global impression of severity at every visit
 Investigator, caregiver, and patient (if able)
clinical global impression of improvement
comparing end of treatment (visit 4/visit 9) to
baseline (visit 2/visit 7) and end of washout (visit
6/visit 10) to end of treatment (visit 4/visit 9)
 Columbia Suicide Severity Rating Scale (203 study
only) [38].
In the extension phase of the IB1001-201 study only,
the Niemann-Pick disease type C Clinical Severity Scale
(NPC-CSS) will be introduced as a secondary endpoint,
where the graduation of changes is expected to detect
clinically relevant changes in functioning/benefit after
1 year of treatment [39].
In addition, the Annual Severity Increment Score [22]
will be assessed in the extension phase.
Safety parameters
Adverse events (serious and non-serious), concomitant
drug and non-drug therapies, safety laboratory blood
samples (hemoglobin, erythrocytes, hematocrit, throm-
bocytes, leukocytes, sodium, lactate dehydrogenase, po-
tassium, creatinine, serum bilirubin level, aspartate
aminotransferase, alanine aminotransferase, urea, alka-
line phosphatase, follicle-stimulating hormone for
postmenopausal women only), and urine samples (leuko-
cytes, nitrite, urobilinogen, protein, pH, occult blood
(erythrocytes, leucocytes), specific gravity, ketones, bili-
rubin, glucose) will be collected routinely throughout
the study. Sparse pharmacokinetic blood sampling will
be conducted at every visit (visit 1–visit 10). Blood sam-
ples for the quantification of N-acetyl-L-leucine in
plasma will be obtained at visit 7 and visit 9. Urine sam-
ples will also be collected for concentrations of N-acetyl-
D-leucine at the time points designated on the schedule
of events (Suppl. Table 1, 2). At visit 1, this urine sample
serves as a key enrollment criterion testing for the use of
the prohibited medication N-acetyl-DL-leucine. Vital
signs, physical exams, height/weight, and electrocardio-
grams will also be collected at the time points designated
on the schedule of events (Suppl. Table 1, 2). A detailed
description of the safety parameters is provided in Suppl.
Material II.
Statistical planning and analyses
The statistical analysis plan details the statistical
methods for analysis for each of the three clinical trials.
Data from the three clinical trials will be analyzed
separately.
The primary analysis population is the modified
intention to treat (mITT) analysis set defined as all pa-
tients who receive at least one dose of study drug (N-
acetyl-L-leucine) and with one video recording at either
visit 1 or visit 2 (or both) and visit 3 or visit 4 (or both).
Analyses will also be conducted on the per protocol ana-
lysis set which will consist of all patients with video re-
cordings at baseline (visit 1 and/or visit 2), end of
treatment (visit 3 and/or visit 4), and end of washout
(visit 5 and/or visit 6) and without any major protocol
deviations that can influence the validity of the data for
the primary efficacy variable.
The primary endpoint will utilize assessments based
on single video recordings at the end baseline period
(visit 2), end of the treatment period (visit 4), and end of
the washout period (visit 6). If the visit 2 video is miss-
ing, the visit 1 video will be used in its place. Similarly, if
the visit 4 and visit 6 videos are missing, visit 3 and visit
5 videos will respectively be used in their place. Analyses
based on the mITT analysis set will utilize a last obser-
vation carried forward approach for missing videos 5
and 6. For the primary endpoint CI-CS, this implies that
the CI-CS value for visit 4 to visit 6 will be assigned the
value 0 if both videos 5 and 6 are not available.
The analysis of the primary endpoint will be based on
a single sample one-sided t test comparing the mean of
the CI-CS differences with zero. The null hypothesis is
that the mean is ≤ 0, with the alternative hypothesis that
this mean is > 0, and the test will be conducted at the
one-sided 5% significance level. The secondary endpoint
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that is based on a 3-point categorization of the CI-CS
will be evaluated based on the Wilcoxon-signed-rank
test. The analysis of the secondary endpoint, Clinical Im-
pression of Severity (CI-S), will be analyzed for the pri-
mary endpoint. All other endpoints will be evaluated
descriptively. There will be no formal control of multi-
plicity across these endpoints.
For each of the primary and secondary endpoints,
there will be evaluation within key subgroups; naïve ver-
sus non-naïve, age (pediatric versus adult), gender (male
versus female), region (USA versus Europe), primary an-
chor test (9HPT-D or 8MWT), patients on miglustat vs
patients not on miglustat (201 study only); Tay-Sachs
versus Sandhoff patients (202 study only), individual
components of SARA scale at baseline: Gait Subtest,
composite of SARA Subtests 1–4 (Gait, Stance, Sitting,
Speech), intra-patient variability between SARA score at
visit 1 (baseline 1) versus visit 2 (baseline 2) (below/
above median) and intra-patient variability between CI-S
score visit 1 (baseline 1) versus visit 2 (baseline 2)
(below/above median). These evaluations will be based
on plotting treatment differences together with 90% con-
fidence intervals within each subgroup.
It is postulated that N-acetyl-L-leucine will show ef-
fectiveness in 30% of patients and this success rate is
viewed as being clinically important. It is assumed that
this group of patients will have scores that are distrib-
uted across the values 1 and 2 for the primary endpoint
with 10% scoring 1 and 20% scoring 2 and further that
the remaining 70% of patients will have scores that are
evenly distributed between the values − 1, 0, and 1. The
resulting mean score is 0.5 and the standard deviation
for the primary endpoint under these assumptions is
then 1.075. With 30 patients reporting on the primary
endpoint, the study will have 80% power to detect a
treatment benefit in a 5% one-sided one-sample t test.
Assuming alternatively that the 30% of patients improv-
ing will have scores that are evenly distributed across the
values 1 and 2, then the mean score for the primary end-
point will be 0.45 with an SD of 1.02. Under these as-
sumptions, the study will have power of 76%.
In observational case-series, N-acetyl-leucine has
demonstrated potential as a broad treatment for the
general symptoms of other progressive, inherited
ataxias [23, 24]. Meta-analyses will therefore be con-
ducted across the three separate studies for NPC, GM2,
and A-T to assess more general question regarding the
effectiveness of N-acetyl-L-leucine for symptoms of
ataxia. A description of Data Collection is provided in
Suppl. Material III.
Discussion
Given the lack of global symptomatic or disease-
modifying therapies for NPC, GM2, or A-T, there is an
urgent need for effective and well-tolerated drug treat-
ments. The open-label, rater-blinded IB1001 master
protocol was designed through a collaboration between
National Regulatory Agencies, leading Clinical Experts,
Patient Organizations, and the industry Sponsor, to ad-
dress of the unique ethical and practical challenges to
conducting clinical trials for these orphan, heterogenous
patient populations, and be better able to capture N-
acetyl-L-leucine’s therapeutic effect and, therefore, best
positioned to expedite the development and availability
of this promising drug candidate [7].
In Sponsor meetings with National Regulatory Author-
ities, methodological and statistical concerns were raised
and discussed, with an emphasis on selecting a specific
primary outcome measure that focuses on the aspects of
the diseases that are relevant and meaningful to patients.
Subsequent interviews with representatives of the patient
communities and leading clinicians, regarding the core
signs/symptoms that are most meaningful for patients
and clinically relevant to physicians, elucidated the key
symptoms that affect patient’s quality of life. These
symptoms, namely gait and fine motor skills, were estab-
lished as the anchor tests.
In the absence of a placebo, to minimize detection bias
in the primary endpoint, the CI-CS assessment was per-
formed by blinded, independent raters. To prevent po-
tential expectation or performance bias, all aspects of
the administration and video recording of the CI-CS an-
chor tests were standardized to ensure the quality of vid-
eos assessed by the blinded raters. Prior to any patient
visit, all sites were trained on these detailed protocols,
including precise verbal instructions, encouragement,
break times between test trials, and instructions on
which trial to video. Given the majority of NPC patients
enrolled in the IB1001-201 clinical trial featured severe
physical impairments with regard to both their fine
motor skills as well as balance and gait, and mild to sig-
nificant levels of cognitive impairment, the potential for
a placebo-effect which significantly altered neurological
signs and symptoms—the basis of the CI-CS assess-
ment—was therefore considered minimal, ensuring the
interpretability of the blinded raters’ CI-CS assessments.
Ultimately, the issues raised during regulatory review
and the feasibility process were instructive to developing
the innovative trial design and adaptive primary out-
come assessment for the IB1001 studies (tailored to the
capabilities of individual patients to maximize inclusion,
and better detect a clinically meaningful treatment ef-
fect). The pathway to the studies approval was facilitated
by frequent communication between all parties, and the
collaborative adaptation of study methodology and stat-
istical approaches ensured the IB1001 trials were feasible
to recruit, tailored to the capabilities of the NPC, GM2,
and A-T patents and, importantly, best positioned to
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detect a meaningful clinical change in patients’ quality of
life.
Trial status
At the time of manuscript submission, the protocol for
IB1001-201 (ES: V4.0, 28 August 2019; DE/UK/SL: V5.0,
14 November 2020; US: V5.1, 14 December 2019),
IB1001-202 (V5.0, 14 November 2019), and IB1001-203
(V5.0, 30 December 2019) have been accepted/approved
in each country where they are respectively planned to
be conducted, including the US Food and Drug Admin-
istrations (201, 202, 203); UK Medicines and Healthcare
products Regulatory Authority (201, 202, 203); German
Federal Institute for Drugs and Medical Devices (201,
202, 203), Spanish Agency of Medicines and Medical
Products (201, 202), and Slovakia Štátny ústav pre kon-
trolu liečiv (201), as well as respective research ethics
committees (REC)/institutional review boards (IRB) (ac-
tive approved protocol version varies based on status of
enrollment per site/per study). The first study partici-
pants were enrolled on 7 June 2019 for IB1001-202
(GM2), 4 September 2019 for IB1001-201 (NPC), and 09
January 2019 for IB1001-203 (A-T). Recruitment for the
IB1001-201 study completed 31 January 2020, and the
parent study completed September 2020 (extension
phase ongoing). Recruitment for the IB1001-202 study
was scheduled to be completed 31 March 2020, and June
2020 for the IB1001-203 study. However, due to the glo-
bal outbreak of COVID-19, further enrollment in these
studies has been delayed and is expected to be com-
pleted in Spring 2021.
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